The anti-cancer effects of frondoside A

Thomas E. Adrian, Peter Collin

Research output: Contribution to journalReview articlepeer-review

25 Citations (Scopus)


Frondoside A is a triterpenoid glycoside from the Atlantic Sea Cucumber, Cucumaria frondosa. Frondoside A has a broad spectrum of anti‐cancer effects, including induction of cellular apoptosis, inhibition of cancer cell growth, migration, invasion, formation of metastases, and angiogenesis. In cell lines and animal models studied to date, the anti‐cancer effects of the compound are seen in all solid cancers, lymphomas, and leukemias studied to date. These effects appear to be due to potent inhibition of p21‐activated kinase 1 (PAK1), which is up‐regulated in many cancers. In mouse models, frondoside A has synergistic effects with conventional chemotherapeutic agents, such as gemcitabine, paclitaxel, and cisplatin. Frondoside A administration is well‐tolerated. No side effects have been reported and the compound has no significant effects on body weight, blood cells, or on hepatic and renal function tests after long‐term administration. Frondoside A may be valuable in the treatment of malignancies, either as a single agent or in combination with other therapeutic modalities.

Original languageEnglish
Article number64
JournalMarine Drugs
Issue number2
Publication statusPublished - Feb 2018


  • Angiogenesis
  • Apoptosis
  • Cancer
  • Frondoside A
  • Invasion
  • Metastases
  • Tumor growth

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'The anti-cancer effects of frondoside A'. Together they form a unique fingerprint.

Cite this